Summary of Key Points Core Viewpoint - Titan Pharmaceuticals, Inc. has completed a private placement of Series B Convertible Preferred Stock with Blue Harbour Asset Management for a total of $1,000,000, with a conversion price set at $3.00 per share [1]. Group 1: Private Placement Details - The private placement involved the sale of 100,000 shares of Preferred Stock to Blue Harbour for an aggregate purchase price of $1,000,000 [1]. - The shares sold in this transaction are not part of a public offering and have not been registered under the Securities Act of 1933, relying on Regulation S [3]. - Titan has entered into a registration rights agreement with Blue Harbour, which outlines certain registration rights upon the occurrence of specified events [3]. Group 2: Ownership Conversion Blocker - The Certificate of Designations for the Preferred Stock includes a beneficial ownership conversion "blocker" that limits Blue Harbour's ability to acquire more than 19.99% of the Company's outstanding common stock without shareholder approval [2]. Group 3: Financial Advisory - ARC Group Ltd. acted as the sole financial advisor to Titan Pharmaceuticals during this private placement [4].

Core Viewpoint - Polyrizon Ltd. has successfully closed a private placement raising approximately $17.0 million through the sale of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit [1][3]. Group 1: Offering Details - The offering included the sale of 35,416,667 Ordinary Units, each comprising one Ordinary Share or Pre-Funded Warrant and one Series A Warrant to purchase one Ordinary Share [2]. - The initial exercise price for each Series A Warrant is set at $1.20 per Ordinary Share, with a term of 30 months, and is subject to shareholder approval [2]. - The Pre-Funded Warrants can be exercised at any time following shareholder approval [2]. Group 2: Use of Proceeds - The net proceeds from the offering, along with existing cash, are intended for general corporate purposes and working capital [3]. Group 3: Company Overview - Polyrizon is a development-stage biotech company focused on innovative intranasal hydrogels that create a barrier against viruses and allergens in the nasal cavity [6]. - The company's proprietary technology, Capture and Contain TM, aims to function as a "biological mask" and is being further developed for drug delivery [6]. - Polyrizon is also working on an earlier-stage technology, Trap and Target ™, for nasal delivery of active pharmaceutical ingredients [6].

Core Viewpoint - Pelangio Exploration Inc. has successfully closed a non-brokered private placement, raising gross proceeds of $1,000,000 through the issuance of 25,000,000 units at a price of $0.04 per unit [1][2]. Group 1: Private Placement Details - Each unit consists of one common share and one common share purchase warrant, with each warrant allowing the purchase of one common share at an exercise price of $0.05 for a period of 36 months [2]. - The company plans to utilize the gross proceeds for working capital, including exploration, metallurgical work, land maintenance costs, and up to 10% for settling non-arm's length payables [3]. Group 2: Regulatory and Compliance Information - No finder's fees are applicable for this private placement, and all securities issued are subject to a statutory four-month hold period [4]. - The private placement is pending final approval from the TSX Venture Exchange [4]. Group 3: Company Overview - Pelangio Exploration focuses on acquiring and exploring land packages in gold-rich regions, specifically in Ghana and Canada, with notable properties including the Manfo and Obuasi properties in Ghana [6].

Core Viewpoint - SINTX Technologies, Inc. has successfully completed a private placement of common stock and warrants, raising approximately $5 million for working capital purposes [1][2]. Group 1: Private Placement Details - The company issued and sold 1,449,287 shares of common stock at a price of $3.45 per share, along with unregistered warrants to purchase an equal number of shares at an exercise price of $3.32 [1][2]. - The offering closed on February 25, 2025, and was facilitated by H.C. Wainwright & Co. as the exclusive placement agent [2]. Group 2: Securities Regulation - The securities were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered under the Act or applicable state securities laws [3]. - The company has agreed to file registration statements with the SEC for the resale of the shares and those issuable upon exercise of the warrants [3]. Group 3: Company Overview - SINTX Technologies is based in Salt Lake City, Utah, and specializes in advanced ceramics for medical applications, particularly silicon nitride, which has been implanted in humans since 2008 [5]. - The company has pursued strategic acquisitions and alliances to expand into new markets [5].

As filed with the U.S. Securities and Exchange Commission on December 20, 2024. Registration No. 333-281806 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ribbon Acquisition Corp (Exact name of registrant as specified in its constitutional documents) Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. ...

As filed with the U.S. Securities and Exchange Commission on December 16, 2024. Registration No. 333-281144 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________ Plum Acquisition Corp. IV (Exact Name of Registrant as Specified in its Charter) ______________________ | Cayman Islands | 6770 | 98-1795710 | | --- | --- | --- | | (State or Other Jurisdiction of | (Primary Standard Industri ...

As filed with the U.S. Securities and Exchange Commission on December 16, 2024. Registration No. 333-281144 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________ Plum Acquisition Corp. IV (Exact Name of Registrant as Specified in its Charter) ______________________ | Cayman Islands | 6770 | 98-1795710 | | --- | --- | --- | | (State or Other Jurisdiction of | (Primary Standard Industri ...

As filed with the U.S. Securities and Exchange Commission on December 5, 2024. Registration No. 333-281806 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ribbon Acquisition Corp (Exact name of registrant as specified in its constitutional documents) Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. E ...

TABLE OF CONTENTS As filed with the U.S. Securities and Exchange Commission on September 17, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Roman DBDR Acquisition Corp. II (Exact name of registrant as specified in its charter) Cayman Islands (State or other jurisdiction of incorporation or organization) 6770 (Primary Standard Industrial Classification Code Number) N/A (I.R.S. Employer Identi ...

As filed with the Securities and Exchange Commission on September 3, 2024 (State or other jurisdiction of incorporation or organization) Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Jet.AI Inc. (Exact name of registrant as specified in its charter.) Delaware 4522 93-2971741 (Primary Standard Industrial Classification Number) (IRS Employer Identification No.) Michael Winston 10845 Griffith Peak D ...